T3D Therapeutics announced the addition of Dr. Suzanne de al Monte to its Advisory Board. Suzanne de la Monte, MD, MPH, is a physician scientist who directs basic and translational research in the laboratory and performs clinical service work in Neuropathology. Her research efforts are mainly focused on understanding the role of insulin and insulin-like growth factor resistance in relation to neurodegeneration caused by Alzheimer’s disease and chronic alcohol abuse. Dr. de la Monte earned her MD degree from Cornell University Medical College, attended the NIH Graduate School, and earned an MPH from the Johns Hopkins University School of Hygiene and Public Health. She served as an intern and resident at Johns Hopkins Hospital, and served as a Resident and Fellow of Neuropathology at Massachusetts General Hospital. Dr. de la Monte was a faculty member at the Massachusetts General Hospital and Harvard Medical School until 2000 when she joined the medical faculty at Rhode Island Hospital and the Alpert Medical School of Brown University where she is Professor in the Departments of Neurology, Neurosurgery, Pathology and Medicine and Director of Core Laboratories at Lifespan Academic Institutions.
- T3D Therapeutics, Inc.: T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer’s Disease
- T3D Therapeutics Receives a Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program
- Alzheimer’s Association Part The Cloud Grant Program Invests $24 Million in 16 Innovative Research Trials
- Leading Alzheimer’s Disease Experts Join T3D Therapeutics’ Scientific Advisory Board
- T3D Therapeutics Begins Enrollment in the PIONEER Phase 2 Clinical Trial of T3D-959 in Patients with Mild to Moderate Alzheimer’s Disease